louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03831737: Team-based Ergonomics Educational Model for Workplace WELLNESS Improvement: A Pilot Study
Official title: Team-based Ergonomics Educational Model for Workplace WELLNESS Improvement: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: MSDs
Muscle Pain
Lead sponsor: Milton S. Hershey Medical Center
Sponsor class: OTHER
First posted: 2019-02-06
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This research is being done to explore the potential benefit of a physical therapist-guided stretching program on musculoskeletal pain and well-being.


Eligibility criteria: Inclusion Criteria:

* HMC/COM staff (faculty, residents, fellows, APPs, physical/occupational therapists, nurses, schedulers, etc.)
* At least 18 years old
* Willing and able to participate in all study procedures
* Willing and able to provide informed consent
* Group 2 subjects must have access to a computer with internet or an iPhone or Android smartphone

Exclusion Criteria:

* Subjects who do not meet all inclusion criteria will be excluded from the study.

Primary outcomes:
measure: SF-36
timeFrame: change from 3 month time point to 6 month time point
measure: CMDQ
timeFrame: change from 3 month time point to 6 month time point
Secondary outcomes:
measure: Modified Sit and Reach
timeFrame: baseline, 3 months, 6 months, change from 3 month time point to 6 month time point
measure: SF-36
timeFrame: baseline, 3 months
measure: CMDQ
timeFrame: baseline, 3 months
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Penn State Health Milton S. Hershey Medical Center
state: Pennsylvania
Study officials:
affiliation: Penn State Health Milton S Hershey Medical Center
name: Aiesha Ahmed, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Milton S. Hershey Medical Center
name: Majid Dadgar-Kiani, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00758537: Tryptophan Metabolism in Kidney Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Kidney Disease
Keywords: Assessment of tryptophan and tryptophan catabolites and IDO-activity in patients with chronic kidney disease
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2008-09-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: tertiary care academic center, university hospital

Brief summary: Tryptophan metabolism in kidney disease will be investigated in patients with chronic kidney disease stages (ADOQI 3-5). Tryptophan levels and respective catabolites will be assessed under hemodialysis.


Eligibility criteria: Inclusion Criteria:

* Chronic kidney disease (for \> 3months) stages (National Kidney foundation/ADOQI): 3-5

Exclusion Criteria:

* Signs of infection or systemic inflammation

Primary outcomes:
measure: Course of plasma tryptophan level and levels of tryptophan metabolites under standard low-flux hemodialysis.
timeFrame: does not apply
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charite University Medicine Berlin
Study officials:
affiliation: Charite University Medicine
name: Petra Reinke, Md PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00154037: Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.
Official title: Characterization of Vascular Effects of Candesartan and Pioglitazone.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Subjects
Keywords: vascular reactivity
venodilation
pulse wave velocity
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2005-09-12
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is designed to test the hypothesis in healthy subjects that candesartan and pioglitazone provide additional vascular relaxing or modulating effects in addition to their blood-pressure and blood glucose level reducing ability, respectively.

Detailed description: The aim of the study is to investigate the effect of oral candesartan and/ or rosiglitazone therapy on the vascular responsiveness of different vasoactive compounds (angiotensin II, insulin, histamine and glyceroltrinitrate) in healthy subjects. Pioglitazone will be given orally (4 weeks 30mg/d, titrated to 45 mg/d for another 4 weeks). Candesartan will be given orally (4 weeks 8mg/d, titrated to 16 mg/d for another 4 weeks) as treatment. Every subject will receive intravenous stimulation with phenylephrine, angiotensin II, histamine, insulin and glyceroltrinitrate before and after an 8 weeks treatment interval with study medication or placebo. In addition, pulse wave velocity will me measured non-invasively before and after treatment.

Eligibility criteria: Inclusion Criteria:

* Male
* healthy
* 18 - 40 years old
* non-smoker
* no additional medication

Exclusion Criteria:

* any relevant disease
* smokers
* elevated liver enzymes
* body weight different from Broca Norm \> 20%
* allergies

Primary outcomes:
measure: Vascular reactivity
Secondary outcomes:
measure: Pulse wave velocity
measure: Changes in Angiotensin metabolites
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Institute of Clinical Pharmacology, Medical Faculty, University of Technology
Study officials:
affiliation: Institute of Clinical Pharmacology
name: Wilhelm Kirch, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01006837: Hypothermia in the Trauma Patient - When do Trauma Patients Get Cold?
Official title: Hypothermia in the Trauma Patient - Temperature Changes During Transport and Initial Treatment in Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypothermia
Keywords: trauma patients
severe injury
ISS ≥9
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Norwegian Air Ambulance Foundation
name: St. Olavs Hospital
First posted: 2009-11-03
Enrollment: 60
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients transported to St. Olavs Hospital (Trondheim, Norway), followed by an anesthesiologist from the norwegian air ambulance and taken care of by the trauma team in the emergency room.

Brief summary: The purpose of this study is to analyze changes in core body- and skin temperature during pre-hospital and early in-hospital treatment of multi-traumatized patients. The researchers want to investigate when trauma patients get cold and to what extent.

Detailed description: Hypothermia is a common finding in severely traumatized patients. Decreases in core temperature during the course of initial evaluation and resuscitation are common, and can contribute to poor outcomes in multi-traumatized patients.

In this study the temperature will be recorded continually with multiple skin probes and an ear-probe from the site of the accident to arrival in the intensive care unit (including time in primary surgery, if any).

Eligibility criteria: Inclusion Criteria:

* trauma patient with a ISS 9 or above.

Exclusion Criteria:

* \<12 years old

Primary outcomes:
measure: Survival to discharge
timeFrame: one year
Secondary outcomes:
measure: Degree of hypothermia
timeFrame: one year
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St. Olavs Hospital, department of anesthesia
Study officials:
affiliation: St. Olavs Hospital
name: Eirik Skogvoll, MD, PhD
role: STUDY_CHAIR
References:
citation: Uleberg O, Eidstuen SC, Vangberg G, Skogvoll E. Temperature measurements in trauma patients: is the ear the key to the core? Scand J Trauma Resusc Emerg Med. 2015 Nov 19;23:101. doi: 10.1186/s13049-015-0178-z.
Clinical trial NCT06438237: Validation of a Prediction Model for Inadequate Bowel Preparation
Official title: Validation of a Prediction Model for Inadequate Bowel Preparation Before Colonoscopy Based on a Systematic Review and Meta-analysis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bowel Preparation
Colonoscopy
Keywords: Bowel preparation for colonoscopy
Lead sponsor: General Hospital of Shenyang Military Region
Sponsor class: OTHER
First posted: 2024-05-31
Enrollment: 615
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients undergoing colonoscopy

Brief summary: We have developed a novel inadequate bowel preparation prediction model based on a systematic review and meta-analysis. The goal of this observational study is to validate the accuracy of this model.

Detailed description: A total of 615 patients undergoing colonoscopy will be enrolled. The primary outcome is quality of bowel preparation. The secondary outcomes include polyp/adenoma detection rate, willingness of undergoing colonoscopy again and adverse events.

Eligibility criteria: Inclusion Criteria:

1. adult patients (age is ≥18 years old);
2. patients undergoing colonoscopy;
3. written informed consent.

Exclusion Criteria:

1. patients undergoing emergent colonoscopy;
2. patients with major psychiatric disorders;
3. pregnant or breast feeding patients;
4. patients with contraindications for colonoscopy (e.g., heart failure, renal insufficiency);
5. patients suspected to have intestinal obstruction, stenosis or perforation;
6. patients previously enrolled in this study.

Primary outcomes:
measure: Quality of bowel preparation
timeFrame: During the procedure of colonoscopy
Secondary outcomes:
measure: Adenoma and/or polyp detection rate
timeFrame: During the procedure of colonoscopy
measure: Number of polyps and/or adenomas
timeFrame: During the procedure of colonoscopy
measure: Adverse events
timeFrame: Before the procedure of colonoscopy
Other outcomes:
Locations:
city: Shenyang
country: China
facility: Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
state: Liaoning
Study officials:
affiliation: Department of Gastroenterology, General Hospital of Northern Theater Command
name: Xingshun Qi
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):620-5. doi: 10.1016/j.gie.2008.05.057. Epub 2009 Jan 10.
Clinical trial NCT02166437: Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese
Official title: Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese, Prospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteoporosis
Keywords: osteoporosis
BMD
teriparatide
bisphosphonate
denosmab
Lead sponsor: Tomidahama Hospital
Sponsor class: OTHER
First posted: 2014-06-18
Enrollment: 500
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: tion Osteoporotic patients who admit to our hospital

Brief summary: In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly divided following daily teriparatide in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.

Detailed description: Registry criteria: Patients treated in the investigators hospital using teriparatide. Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (\< young adult mean 65%).

Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants

Eligibility criteria: Inclusion Criteria:

* severe osteoporotic patients

Exclusion Criteria:

* cancer, hypercalcemia, etc (i.e. patients who could not use bisphosphonate, denosmab, teriparatide)

Primary outcomes:
measure: Clinical results of bisphosphonate vs. denosmab following daily teriparatide treatment
timeFrame: Up to 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Yokkaichi
country: Japan
facility: Tomidahama Hospital
state: Mie
Study officials:
affiliation: Tomidahama Hospital
name: Rui Niimi, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06537037: Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary）
Official title: Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary）
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Urologic Cancer
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2024-08-05
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated for urologic cancer

Brief summary: This is the prospective, observational cohort study (Radiogenomics-Urinary), which aims to explore the relationship between the imaging information of urologic cancer patients, tumor microenvironment and the prognosis of urologic cancer patients.


Eligibility criteria: Inclusion Criteria:

1. Patients treated for urologic cancer in Wuhan Union Hospital from August 2024 to August 2027;
2. Aged \> 18 years old;
3. At least one CT scan or MRI scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria：

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than urologic cancer;
4. Unclear pathological diagnosis。

Primary outcomes:
measure: Correlation analysis of sequencing results and body composition
timeFrame: 0.5 year
measure: Correlation analysis of sequencing results and tumor radiomic features
timeFrame: 0.5 year
Secondary outcomes:
measure: Constructing tumor microenvironment prediction model
timeFrame: 2 years
measure: Constructing a multi-dimensional prognostic prediction model
timeFrame: 3 years
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT03128437: Anxiety, Mood, and Health Behaviors in Young Adults
Official title: The Relationship Between Anxiety, Mood, and Health Behaviors in Young Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety Sensitivity
Keywords: Anxiety
Young Adults
Health Behaviors
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
First posted: 2017-04-25
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This is a randomized control trial to test the effect of an anxiety sensitivity intervention on health behaviors among 18-35 year-olds.

Detailed description: This is a 2-arm randomized control trial to test the effect of an anxiety sensitivity intervention on health behaviors among 18-35 year-olds. Participants will be 18-35 year-olds with high anxiety sensitivity randomized to 1)Exercise Exposure Intervention or 2)Assessment Only Control Condition. Participants in both groups will be followed for 8 weeks.

Eligibility criteria: Inclusion Criteria:

* Ages 18-35
* Elevated anxiety sensitivity (ASI-3 score \>=23)
* Able to safely participate in moderate-intensity physical activity as assessed by the Physical Activity Readiness Questionnaire (PAR-Q), which will be administered during screening

Exclusion Criteria:

* Current aerobic exercise routine - Measured using the L-CAT with an established cut point of \>2 (assessed at screening)
* Receiving ongoing psychotherapy or counseling (Self-report at screening)
* Recent change in psychotropic medication for anxiety (Self-report at screening)
* Psychiatric hospitalization in past 6 months (Self-report at screening)
* Current pregnancy (Self-report at screening)

Primary outcomes:
measure: Anxiety sensitivity
timeFrame: 4 weeks
Secondary outcomes:
measure: Physical activity
timeFrame: 4 & 8 weeks
measure: Anxiety sensitivity
timeFrame: 8 weeks
measure: Heart rate variability
timeFrame: 2 weeks
measure: Alcohol use
timeFrame: 4 & 8 weeks
measure: Binge eating
timeFrame: 4 & 8 weeks
measure: Sleep
timeFrame: 4 & 8 weeks
measure: Exercise Stage of Change
timeFrame: 4 & 8 Weeks
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Virginia Commonwealth University, School of Medicine
state: Virginia
Study officials:
affiliation: Virginia Commonwealth University
name: Jessica LaRose, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lanoye A, Rybarczyk B, Evans R, Leahey T, LaRose J. Pilot randomized clinical trial targeting anxiety sensitivity: effects on physical activity. Cogn Behav Ther. 2022 May;51(3):257-271. doi: 10.1080/16506073.2021.1954082. Epub 2021 Aug 10.
Clinical trial NCT01619137: Soap Versus Normal Salin Plus Povidone-iodine in Ununion Wound
Official title: Comparison of the Effect of Water and Soap Irrigation With With Povidone-iodine And Normal Salin Treatment of Patients With Ununion Laparatomy or Episiotomy Wound ( a Pilot Study)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Wound
Keywords: ununion wound
soap
irrigation
Povidone-iodine
normal salin
Lead sponsor: Hormozgan University of Medical Sciences
Sponsor class: OTHER
First posted: 2012-06-14
Enrollment: 40
Sex: FEMALE
Minimum age (years): 10
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparison of the effect of water and soap irrigation with Povidone-iodine And normal salin treatment of patients with ununion laparatomy or episiotomy wound ( a pilot study)

Detailed description: IN Comparison of the effect of water and soap irrigation with Povidone-iodine And normal salin treatment of patients with ununion laparatomy or episiotomy wound ( a pilot study), We use soap in one group and Povidone-iodine And normal salin in other group for irrigation of ununion laparatomy or episiotomy wound.it's require the patients in Povidone-iodine And normal salin group be at hospital till wound be able to closed.

Eligibility criteria: Inclusion Criteria:

* all the women coming to Shariati hospital or Gynecologist's office with complain of ununion wound of laparatomy or episiotomy enroll to this study

Exclusion Criteria:

* patients not satisfacted to participant in the study exclude of it

Primary outcomes:
measure: number of admission day
timeFrame: 1 month
Secondary outcomes:
measure: complication of each treatment
timeFrame: 1 months
Other outcomes:
Locations:
city: Bandarabbas
country: Iran, Islamic Republic of
facility: Bandarabbas
state: Hormozgan
Study officials:
affiliation: Hormozgan University of Medical Science (HUMS)
name: Aida Najafian
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03346837: A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
Official title: A Randomized, Open-Label, Four-Cohort, Parallel Design Study to Evaluate the Effect of Itraconazole or Rifampin on the Single-Dose Pharmacokinetics of BMS-986205 in Normal Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Malignancies Multiple
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2017-11-17
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.

Detailed description: A randomized, open-label, parallel design study in healthy participants to assess the effects of itraconazole and rifampin on the single-dose pharmacokinetics of BMS-986205. Safety and tolerability data to be collected and assessed as well.

Eligibility criteria: Inclusion Criteria:

* Body mass index 18.0 to 32.0 kg/m2, inclusive
* Must have normal renal function demonstrated by GFR, calculated by Chronic Kidney Disease Epidemiology Collaboration formula
* Women must not be of childbearing potential (cannot become pregnant)

Exclusion Criteria:

* Any significant acute or chronic medical illness
* History of glucose-6-phosphodiesterase (G6PD) deficiency
* Personal or family history of cytochrome b5 reductase deficiency

Other protocol defined inclusion / exclusion criteria could apply

Primary outcomes:
measure: Maximum observed plasma concentration (Cmax)
timeFrame: Up to 25 days
measure: AUC from time zero to time of last quantifiable concentration (AUC(0-T))
timeFrame: Up to 25 days
measure: AUC from time zero extrapolated to infinite time (AUC(INF))
timeFrame: Up to 25 days
Secondary outcomes:
measure: Incidence of Adverse Events (AEs)
timeFrame: Up to 25 days
measure: Incidence of Serious Adverse Events (SAEs)
timeFrame: Up to 76 days
measure: Number of participants with electrocardiogram abnormalities
timeFrame: Up to 25 days
measure: Number of participants with physical examination findings abnormalities
timeFrame: Up to 25 days
measure: Number of participants with clinical laboratory abnormalities
timeFrame: Up to 25 days
Other outcomes:
Locations:
city: Austin
country: United States
facility: PPD
state: Texas
Study officials:
affiliation: Briston-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References: